|
The Food
and Drug Administration (FDA) has permitted a new medicine for treating erectile
dysfunction. Created by the Bayer Corp. in Germany and to be dispersed in the
 U.S.
by Glaxo Smith Kline, the new oral drug called Levitra (vardenafil), will
contend with Viagra in the sexual tonic market.
[FDA press
release] The Food and Drug Administration nowadays permitted Levitra (vardenafil),
an oral medication to cure for erectile dysfunction in men (impotence). This is
the subsequent oral product permitted for the treatment of erectile dysfunction.
Erectile
dysfunction influences millions of men in the United States. Levitra acts by
calming muscles in the penis and blood vessels, allowing amplified blood flow
into the penis, which makes an erection.
Levitra
was estimated in randomized, placebo-controlled trials involving in excess of
2000 men with erectile dysfunction. In two of the testing men had erectile
dysfunction related with diabetes mellitus or following drastic prostatectomy
for prostate cancer.
The drugs
efficiency was assessed using a sexual utility survey. Additionally, patients
were asked to statement if they were competent to achieve an erection sufficient
for interaction and whether the erection was preserve to allow conclusion of
intercourse. In all of the experiment, Levitra enhanced patient’s ability to
attain and maintain a penile erection.
The suggested dose
is 10 mg taken 1 hour earlier than sexual movement. An upper dose of 20 mg is
accessible for patients whose reaction to the 10 mg dose is not sufficient. Two
minor doses (2.5 mg plus 5.0 mg) are also accessible and may be needed for
patients taking other pills or have medical circumstances that may reduce the
body’s capability to metabolize vardenafil. Levitra should not be used extra
than once a day.
|